Peptide blocking of IgE/receptor interaction: Possibilities and pitfalls

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 12, 1997, Pages 1155-1169

  Helm, B A ^a   Spivey, A C ^a   Padlan, E A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; FC RECEPTOR; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; PEPTIDE;

ANIMAL CELL; DRUG DESIGN; DRUG STRUCTURE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; REVIEW;

EID: 0031438299     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb02518.x     Document Type: Review

References (102)

1. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. J Immunol 1966;97:840-5.
2. Bennich H, Ishizaka K, Johansson SGO, et al. A new class of human immunoglobulins. Bull World Health Organ 1968;38:151-4.
3. Hagan P, Blumenthal V, Dunn G. Human IgE, IgG4 and resistance to re-infection with Schistosoma haematobium. Nature 1991;349:243-5.
4. Gounni AS, Lamkhioued B, Ochiai K, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-6.
5. Cookson WOCM, Moffat M. Asthma: an epidemic in the absence of infection. Science 1997;275:41-2.
6. Gaskell D. Allergy, an epidemic of our time. Chem Br 1996;5:6-8.
7. Takenada H, Zhang K, Diaz-Sanchez D, et al. Enhanced human IgE production results from exposure to the aromatic hydrocarbons from diesel exhaust: direct effects on B cell IgE production. J Allergy Clin Immunol 1995;95:103-15.
8. Brostoff J, Gamlin L. A modern disease. In: Hay fever. London: Bloomsbury, 1993:49-64.
9. Shirakawa T, Enomoto T, Shimazu S, et al. The inverse relationship between tuberculin responses and atopic disorder. Science 1997;275:77-9.
10. Stanworth DR, Humphrey JH, Bennich HH, et al. Inhibition of Prausnitz-Küstner reaction by proteolytic cleavage fragments of a human myeloma protein of immunoglobulin class E. Lancet 1968;2:17-18.
11. Ishizaka K, Ishizaka T, Lee EH. Biologic function of the Fc fragments of E myeloma protein. Immunochemistry 1970;7:687-95.
12. Capron A, Dessaint JP, Capron M, et al. From parasites to allergy: a second receptor for IgE. Immunol Today 1986;7:15-17.
13. Blank U, Ra C, Miller K, et al. Complete structure and expression in transfected cells of the high-affinity IgE receptor. Nature 1989;337:187-9.
14. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991;9:457-92.
15. Maurer D, Fiebiger E, Reininger B, et al. Expression of functional high-affinity IgE receptors on monocytes of atopic individuals. J Exp Med 1994;179:745-50.
16. εRI or to calcium ionophores. Nature 1989;339:64-6.
17. Schwartz LB. Human mast cell neutral proteases: markers of mast cell heterogeneity and function. In: Pichler WJ, Stadler BM, Dahinden C, et al., editors. Progress in allergy and clinical immunology. Vol. 1. Toronto: Hogrefe & Huber, 1989:1-5.
18. εRII on human epidermal Langerhans cells by human recombinant IL-4. J Exp Med 1989;170:309-14.
19. Vercelli D, Geha R. Regulation of human IgE synthesis, a tale of two signals. Eur J Allergy Clin Immunol 1989;88:285-92.
20. Mills FC, Thyrophronitis F, Finkelman F, et al. Ig μ-ε isotype switch in IL-4 treated human lymphoblastoid cells. J Immunol 1992;149:1075-80.
21. Abeshira-Amar O, Gilbert M, Jolly J, et al. IL-4 plays a dominant role in the differential development of Th0 into Th1 and Th2 cells. J Immunol 1992;148:3820-5.
22. Hendersen WR, Chi E, Klebanoff SJ. Eosinophil peroxidase induced mast cell secretion. J Exp Med 1980;152:265-8.
23. Lagunoff D, Martin TW. Agents that release histamine from mast cells. Annu Rev Pharmacol Toxicol 1983; 23:331-62.
24. Ohno Y, Tanno K, Yamuchi K, et al. Gene expression and production of tumour necrosis factor by a rat basophilic leukaemia cell line with IgE receptor triggering. Immunology 1990;70:88-96.
25. Vogel M, Miescher S, Biaggi C, et al. Human anti-IgE antibodies by repertoire cloning. Eur J Immunol 1994;24:1200-7.
26. de Weck AL, Stadler B. Good or bad IgE and anti-IgE antibodies: new molecular concepts. In: Kraft D, Sehon A, editors. Molecular biology and immunology of allergens. Boca Raton, FL: CRC Press, 1993:101-12.
27. Shibazaki M, Sumazaki R, Isoyama S, et al. Interaction of lectins with human IgE: IgE binding property and histamine releasing activity of twelve plant lectins. Int Arch Allergy Immunol 1992;98:18-25.
28. Machado DC, Horton D, Harrop R, et al. Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of antigen-specific IgE. Eur J Immunol 1996;26:2972-80.
29. Lindstrom-Bahr H. Human immunoglobulin E: structural studies on the epsilon chain ND. PhD thesis, 1970, University of Uppsala.
30. Helm BA, Ling Y, Teale C, et al. The nature and importance of the inter-ε-chain disulphide bonds in human IgE. Eur J Immunol 1991;21:1543-8.
31. Padlan EA, Helm BA. A modeling study of the α-subunit of human high-affinity receptor for IgE. Receptor 1992;2:129-44.
32. Padlan EA, Helm BA. Modelling studies of IgE/receptor interactions. Biochem Soc Trans 1993;21:963-7.
33. Robertson MW, Liu FT. IgE structure function relationship defined by antibodies induced by synthetic peptides. Mol Immunol 1988;25:103-13.
34. Helm BA, Marsh P, Vercelli D, et al. The mast cell binding site in human IgE. Nature 1988;331:180-3.
35. Helm BA, Kebo D, Vercelli D, et al. Blocking of passive sensitisation of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human epsilon chain fragment of 76 amino acids. Proc Natl Acad Sci U S A 1989;186:9465-9.
36. Marsh P, Helm BA, Gould HJ. IgE in allergic inflammation. Johansson SGO, editor. Pharmacia Allergy Research Foundation, Uppsala, Sweden, pp. 26-31.
37. Stanworth DR, Jones VM, Lewin I, et al. Allergy treatment with an anti-peptide vaccine. Lancet 1990;336:1279-83.
38. Burt DS, Stanworth DR. Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides. Eur J Immunol 1987;17:437-40.
39. Weetall M, Shopes B, Holowka D, et al. J Immunol 1990;145:3849-54.
40. Nio N, Seguro K, Aryoshi Y, et al. Peptide inhibition of allergic responses by synthetic immunoglobulin E peptide fragments and the delineation of the binding sites in the immunoglobulin E molecule to the Fc receptor. Pept Chem 1989;2:203-6.
41. Blank U, Ra C, Miller L, et al. Complete structure and expression in transfected cells of high-affinity IgE receptor. Nature 1989;337:187-9.
42. Wilson APM, Pullar CE, Camp AM, et al. Human IgE mediates stimulus secretion coupling in rat basophilic leukaemia cells transfected with the α-chain of the human high-affinity receptor. Eur J Immunol 1993;23:240-4.
43. Hamburger RN. Peptide inhibition of the Prausnitz-Küstner reaction. Science 1975;189:389-90.
44. Hahn GS. Immunoglobulin derived drugs. Nature 1986;324:283-4.
45. Hamburger RN, Hahn GS, Daigle AE, et al. Results of clinical trials of the IgE pentapeptide. In: Pichler WJ, Stadler BM, Dahinden C, et al., editors. Progress in allergy and clinical immunology. Vol. 1. Toronto: Hogrefe & Huber, 1989:109-14.
46. ε receptor binding site to the third constant region domain of IgE. EMBO J 1991;10:101-9.
47. Nissim A, Schwarzbaum S, Siraganian R, et al. Fine specificity of the IgE interaction with the low and high affinity Fc receptor. J Immunol 1993;150:1365-74.
48. Basu M, Hakimi J, Dharm E, et al. Purification and characterisation of human recombinant IgE-Fc fragments that bind to the human high-affinity IgE receptor. J Biol Chem 1993;268:13118-27.
49. Presta L, Shields R, O'Connel L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:26368-73.
50. εRI interaction. Biochem Soc Trans 1993;21:968-72.
51. Sutton BJ, Gould HJ. The human IgE network. Nature 1993;366:421-8.
52. Helm BA, Sayers I, Higginbottom A. Identification of the high-affinity receptor binding region in human IgE. J Biol Chem 1996;271:7494-7500.
53. Hakimi J, Seals C, Kondas JA. The α-subunit of the human IgE receptor is sufficient for high-affinity IgE binding. J Biol Chem 1990;265:22079-81.
54. Riske F, Hakimi J, Mallamaci M. Human high-affinity receptor for IgE: analysis of functional domains of the α-subunit with monoclonal antibodies. J Biol Chem 1991; 266:11245-51.
55. εRI. Eur J Immunol 1993;23:640-5.
56. Robertson MW. Phage and Escherichia coli expression of the human high affinity immnunoglobulin α-subunit ecto-domain. J Biol Chem 1993;268:12736-43.
57. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994;5:1-39.
58. εRIα subunit which are involved in binding human and rat IgE. J Biol Chem 1993;268:22076-83.
59. McDonnell JM, Beavil AJ, Mackay GA, et al. Structure based design of peptides that inhibit IgE binding to its high affinity receptor. Biochem Soc Trans 1997;25:387-92.
60. εRI α-chain and IgE fragments in Pichia pastoris. PhD thesis, 1997, University of Sheffield.
61. Clackson JA, Wells A. A hot spot of binding energy in a hormone receptor interface. Science 1995;267:383-5.
62. Sayers I. Protein engineering of recombinant human immunoglobulin E: mapping the Fc receptor-binding regions. PhD thesis, 1997, University of Sheffield.
63. Jarrett E, Mackenzie S, Bennich HH. Parasite-induced non-specific IgE does not protect against allergic reactions. Nature 1981;283:302-4.
64. Presta L, Lahr S, Shields RL, et al. Humanisation of an antibody directed against IgE. J Immunol 1993;151: 1632-7.
65. Yagi S, Yanagida M, Tanida I, et al. High level expression of the truncated α chain of human high-affinity receptor for IgE as a soluble form by baculovirus infected insect cells - biochemical characterisation of the recombinant product. Eur J Biochem 1994;220:593-8.
66. εRI and in solution. Biochemistry 1991;30:9125-36.
67. Janetka JW, Raman P, Satyshur K, et al. Novel cyclic biphenyl ether peptide β-strand mimetics and HIV protease inhibitors. J Am Chem Soc 1997;119:441-9.
68. Gallop MA, Barrett RW, Dower WJ, et al. Applications of combinatorial technologies to drug discovery. Background and peptide combinatorial libraries. J Med Chem 1994;37:1233-51.
69. Gordon EM, Barrett RW, Dower WJ, et al. Applications of combinatorial technologies to drug discovery. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem 1994;37:1385-1401.
70. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
71. Willett P. A review of three-dimensional chemical structure retrieval systems. J Chemometrics 1992;6:289-305.
72. Jackson S, DeGrado W, Dwivedi A, et al. Template-constrained cyclic peptides: design of high-affinity ligands for GPIIb/IIIa. J Am Chem Soc 1994;116:3220-6.
73. ε receptor I. J Immunol 1966;157:221-30.
74. Spatola AF, Romanovskis P. Cyclic peptide libraries: recent developments. In: Jung C, editor. Combinatorial peptide and nonpeptide libraries - a handbook. Weinheim: VCH, 1996:327-47.
75. Adang AEP, Hermkens PHH, Linders JTM, et al. Case histories of peptidomimetics: progression from peptides to drugs. Recl Trav Chim Pays-Bas 1994;113:63-78.
76. Gante J. Peptidomimetics-tailored enzyme inhibitors. Angew Chem Int Ed Engl 1994;33:1699-1720.
77. Giannis A, Kolter K. Peptidomimetics for receptor ligands - discovery, development, and medical perspectives. Angew Chem Int Ed Engl 1993;32:1244-67.
78. Marshall GR. A hierarchical approach to peptidomimetic design. Tetrahedron 1993;49:3547-55.
79. Pelton JT, Kazmierski W, Gulya K, et al. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ opioid receptors. J Med Chem 1986;29:2370-5.
80. Alberg DG, Schreiber SL. Structure-based design of a cyclophilin-calcineurin bridging ligand. Science 1993; 262:248-50.
81. Katz BA, Johnson CR, Cass RT. Structure-based design of high affinity streptavidin binding cyclic peptide ligands containing thioether cross-links. J Am Chem Soc 1995;117: 8541-7.
82. Bisang C, Weber C, Robinson JA. Protein loop mimetics: a diketopiperazine-based template to stabilize loop conformations in cyclic peptides containing the NPNA and RGD motifs. Helv Chim Acta 1996;79:1825-42.
83. Muller G. The β-turn as selectivity switch: βI or βII? That is the question. Angew Chem Int Ed Engl 1996;35:2767-9.
84. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-63.
85. Livnah O, Stura EA, Johnson DL, Middleton SA, et al. A functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. Science 1996;273:464-71.
86. Beeley N. Peptidomimetics and small-molecule drug design: towards improved bioavailability and in vivo stability. Trends Biotechnol 1994;12:213-16.
87. Li S, Gao J, Satoh T, et al. A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. Proc Natl Acad Sci U S A 1997;94:73-8.
88. Pfeifer ME, Linden A, Robinson JA. Synthesis of a novel tricyclic dipeptide template and its incorporation into a cyclic peptide mimetic containing an NPNA motif. Helv Chim Acta 1997;80:1513-27.
89. Tilley JW, Chen L, Fry DC, et al. Identification of a small molecule inhibitor of the IL-2/IL-2Rα receptor interaction which binds to IL-2. J Am Chem Soc 1997;119:7589-90.
90. Sarabu R, Lovey K, Madison VS, et al. Design, synthesis and three-dimensional structural characterisation of a constrained Ω-loop excised from interleukin-1α. Tetrahedron 1993;49:3629-40.
91. Kahn M. Peptide secondary structure mimetics: recent advances and future challenges. Synlett 1993;821-6.
92. Olsen GL, Bolin DR, Bonner MP. Concepts and progress in the development of peptide mimetics. J Med Chem 1993;36:3039-49.
93. Beeli R, Steger M, Linden A, et al. A tricyclic template derived from (2S,4R)-4-hydroxyproline for the synthesis of protein loop mimetics. Helv Chim Acta 1996;79:2235-48.
94. Weiss GA, Collins EJ, Garboczi DN, et al. A tricyclic ring system replaces the variable regions of peptides presented by three alleles of human MHC class I molecules. Chem Biol 1995;2:401-7.
95. Ulusse L, Cubillos J, Chmielewski J. Photoregulation of cyclic peptide conformation. J Am Chem Soc 1995;117: 8466-7.
96. Geha RS, Helm B, Gould HJ. Inhibition of Prausnitz-Küstner reaction by an immunoglobulin ε-chain fragment synthesised in E. coli. Nature 1984;315:577-8.
97. Stadler BM, Rudolf MP, Vogel M, et al. Can active immunisation redirect an anti-IgE response? Int Arch Allergy Immunol 1997 (in press).
98. Oettgen HC, Martin TR, Wynshawboris A, et al. Active anaphylaxis in IgE deficient mice. Nature 1994;370: 367-70.
99. Lofts FJ, Hurst HC, Sternberg MJE, et al. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993;8:2813-20.
100. Manolis N, Collier S, Taylor J, et al. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997;3:84-8.
101. εRI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE dependent reactions. J Exp Med 1997;185:663-72.
102. Bruggemann M, Williams G, Bindon C, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimaeric antibodies. J Exp Med 1987;166:1351-61.